Verrucae (synonym: warts) are one of the most common viral infections of humans in which the most frequently used modalities of treatment involve destruction of the affected area, which does not prevent recurrences and often results in scarring. In the present study oral zinc sulphate, an immunomodulator was evaluated as a treatment modality for warts. A placebo-controlled, single-blinded study was conducted on one hundred OPD patients with various types of verrucae. Fifty patients were put on oral zinc sulphate at dose of 5mg/kg for six weeks, while an equal number of patients received placebo for the same duration. In the patients who received oral zinc sulphate, 60.97% showed complete response at the end of six weeks in comparison to 6.45% partial response in the placebo group. The resolution of the lesions occurred with restoration of normal epidermal texture with transient alteration in pigmentation.
Background:Epidermolysis Bullosa (EB) is a genetically determined mechano-bullous disorder of the skin encompassing a group of conditions that share skin fragility as a common feature.Materials and Methods:Twele patients with Epidermolysis Bullosa from Kashmir valley are reported.Results:Our series included 12 patients, 5 males and 7 females. Features were consistent with EB simplex in 8 patients, EB pruriginosa in 2 patients, generalized atrophic benign EB in one patient and EB acquista in one patient.Conclusion:EB is a rare, genetically determined, blistering disorder affecting both males and females with predominant involvement of hands and feet. In the absence of specific therapy, treatment mainly involves avoidance of provoking factors, prevention and treatment of complications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.